125 results on '"Wander, G."'
Search Results
2. Application of Natural Organic Residues as Adsorbents to Remove Lead from Waters
- Author
-
Oliveira, Luciana C., Botero, Wander G., Farias, Tamyris S., Santos, Josué C. C., Gabriel, Gabriele V. M., Goveia, Danielle, Cacuro, Thiago A., and Waldman, Walter R.
- Published
- 2019
- Full Text
- View/download PDF
3. LIGAND SIZE POLYDISPERSITY EFFECT ON SSCP SIGNAL INTERPRETATION
- Author
-
Rocha, Luciana S., Botero, Wander G., Alves, Nuno G., Moreira, José A., da Costa, Ana M. Rosa, and Pinheiro, José Paulo
- Published
- 2015
- Full Text
- View/download PDF
4. Reproductive health in adults with congenital heart disease: a review on fertility, sexual health, assisted reproductive technology and contraception.
- Author
-
van der Zande, J.A., Wander, G., Ramlakhan, K.P., Roos-Hesselink, J.W., and Johnson, M.R.
- Subjects
REPRODUCTIVE technology ,CONGENITAL heart disease ,REPRODUCTIVE health ,CONTRACEPTION ,SEXUAL health - Abstract
Due to the improved survival in individuals with congenital heart disease (CHD), considering their reproductive health has become more important. Currently, this topic is still underexplored. We discuss fertility, sexuality, assisted reproductive technology (ART), and contraception in adults with CHD. Timely counseling regarding fertility, sexuality, pregnancy, and contraception is necessary, preferably during teenage years. Due to a lack of data, whether or not to perform ART in adults with CHD is almost always based on expert opinion and follow-up in an expert center is recommended. Future research is necessary to fill the gaps in knowledge on the risks and frequency of complications of ART in adults with CHD, but also to be able to differentiate the relative risks in the different types of CHD. Only then will we be able to counsel adults with CHD correctly and not unjustly deprive someone of a chance of pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Cyanogenic Residues: Environmental Impacts, Complexation with Humic Substances, and Possible Application as Biofertilizer
- Author
-
Souza, Shenia O., Oliveira, Luciana C., Cavagis, Alexandre D. M., and Botero, Wander G.
- Published
- 2014
- Full Text
- View/download PDF
6. A rare case of double orifice mitral valve with perimembranous ventricular septal defect: Application of three-dimensional echocardiography for clinical decision making
- Author
-
Tandon Rohit, Takkar Shibba, Kumbhkarni Shailender, Kumar Naveen, Aslam Naved, Mohan Bishav, and Wander G
- Subjects
Double orifice mitral valve ,real-time three-dimensional echocardiography ,Medicine ,Pediatrics ,RJ1-570 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Double orifice mitral valve (DOMV) is an uncommon anomaly of surgical importance characterized by a mitral valve with a single fibrous annulus with two orifices opening into the left ventricle (LV). Subvalvular structures, especially the tensor apparatus, invariably show various degrees of abnormality. Associated congenital heart defects are common, though DOMV can occur as an isolated anomaly. Two-dimensional echocardiography is useful for diagnosis but combining it with real-time three-dimensional echocardiography helps in a more detailed evaluation of mitral valve and subvalvular structures as is shown in this case description.
- Published
- 2010
7. Intravaginal misoprostol versus intracervical dinopristone for induction of labour: EP7.126
- Author
-
Tandon, P and Wander, G
- Published
- 2014
8. Can early second trimester serum β-hCG, serum cholesterol and triglycerides be markers of subsequent hypertensive disorders of pregnancy (HDP)?: EP13.37
- Author
-
Wander, G, Modi, D, and Pagi, S L
- Published
- 2013
- Full Text
- View/download PDF
9. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
- Author
-
McMurray, John J.V., Anand, Inder S., Diaz, Rafael, Maggioni, Aldo P., OʼConnor, Christopher, Pfeffer, Marc A., Solomon, Scott D., Tendera, Michal, van Veldhuisen, Dirk J., Albizem, Moetaz, Cheng, Sunfa, Scarlata, Debra, Swedberg, Karl, Young, James B., Amuchastegui, M., Belziti, C., Bluguermann, J., Caccavo, M., Cartasegna, L., Colque, R., Cuneo, C., Fernandez, A., Gabito, A., Goicochea, R., Gonzalez, M., Gorosito, V., Grinfeld, L., Hominal, M., Kevorkian, R., Litvak Bruno, M., Llanos, J., Mackinnon, I., Manuale, O., Marzetti, E., Nul, D., Perna, E., Riccitelli, M., Sanchez, A., Santos, D., Schygiel, P., Toblli, J., Vogel, D., Aggarwal, A., Amerena, J., De Looze, F., Fletcher, P., Hare, D., Ireland, M., Krum, H., Lattimore, J., Marwick, T., Sindone, A., Thompson, P., Waites, J., Altenberger, J., Ebner, C., Lenz, K., Pacher, R., Poelzl, G., Charlier, F., de Ceuninck, M., De Keulenaer, G., Dendale, P., Maréchal, P., Mullens, W., Thoeng, J., Vanderheyden, M., Vanhaecke, J., Weytjens, C., Wollaert, B., Albuquerque, D., Almeida, D., Aspe y Rosas, J., Bocchi, E., Bordignon, S., Clausell, N., Kaiser, S., Leaes, P., Martins Alves, S., Montera, M., Moura, L., Pereira de Castro, R., Rassi, S., Reis, A., Saraiva, J., Simões, M., Souza Neto, J., Teixeira, M., Benov, H., Chompalova, B., Donova, T., Georgiev, P., Gotchev, D., Goudev, A., Grigorov, M., Guenova, D., Hergeldjieva, V., Ivanov, D., Kostova, E., Manolova, A., Marchev, S., Nikolov, F., Popov, A., Raev, D., Tzekova, M., Czarnecki, W., Giannetti, N., Haddad, H., Heath, J., Huynh, T., Lepage, S., Liu, P., Lonn, E., Ma, P., Manyari, D., Moe, G., Parker, J., Pesant, Y., Rajda, M., Ricci, J., Roth, S., Sestier, F., Sluzar, V., Sussex, B., Vizel, S., Antezana, G., Bugueno, C., Castro, P., Conejeros, C., Manriquez, L., Martinez, D., Potthoff, S., Stockins, B., Vukasovic, J., Gregor, P., Herold, M., Jerabek, O., Jirmar, R., Kuchar, R., Linhart, A., Podzemska, B., Soucek, M., Spac, J., Spacek, R., Vodnansky, P., Bronnum-Schou, J., Clemmensen, K., Egstrup, K., Jensen, G., Kjoller-Hansen, L., Kober, L., Markenvard, J., Rokkedal, J., Skagen, K., Torp-Pedersen, C., Tuxen, C., Videbak, L., Laks, T., Vahula, V., Harjola, V., Kettunen, R., Kotila, M., Bauer, F., Cohen Solal, A., Coisne, D., Davy, J., De Groote, P., Dos Santos, P., Funck, F., Galinier, M., Gibelin, P., Isnard, R., Neuder, Y., Roul, G., Sabatier, R., Trochu, J., Anker, S., Denny, S., Dreykluft, T., Flesch, M., Genth-Zotz, S., Hambrecht, R., Hein, J., Jeserich, M., John, M., Kreider-Stempfle, H., Laufs, U., Muellerleile, K., Natour, M., Sandri, M., Schäufele, T., von Hodenberg, E., Weyland, K., Winkelmann, B., Tse, H., Yan, B., Barsi, B., Csikasz, J., Dezsi, C., Edes, I., Forster, T., Karpati, P., Kerekes, C., Kis, E., Kosa, I., Lupkovics, G., Nagy, A., Preda, I., Ronaszeki, A., Tomcsanyi, J., Zamolyi, K., Agarwal, D., Bahl, V., Bordoloi, A., Chockalingam, K., Chopda, M., Chopra, V., Dugal, J., Ghaisas, N., Ghosh, S., Grant, P., Hiremath, S., Iyengar, S., Jagadeesa Subramania, B., Jain, P., Joshi, A., Khan, A., Mullasari, A., Naik, S., Oomman, A., Pai, V., Pareppally Gopal, R., Parikh, K., Patel, T., Prakash, V., Sastry, B., Sathe, S., Sinha, N., Srikanthan, V., Subburamakrishnan, P., Thacker, H., Wander, G., Admon, D., Katz, A., Klainman, E., Lewis, B., Marmor, A., Moriel, M., Mosseri, M., Shotan, A., Weinstein, J., Zimlichman, R., Agostoni, P., Albanese, M., Alunni, G., Bini, R., Boccanelli, A., Bolognese, L., Campana, C., Carbonieri, E., Carpino, C., Checco, L., Cosmi, F., DʼAngelo, G., De Cristofaro, M., Floresta, A., Fucili, A., Galvani, M., Ivleva, A., Marra, S., Musca, G., Peccerillo, N., Perrone Filardi, P., Picchio, E., Russo, T., Scelsi, L., Senni, M., Tavazzi, L., Erglis, A., Jasinkevica, I., Kakurina, N., Veze, I., Volans, E., Bagdonas, A., Berukstis, E., Celutkiene, J., Dambrauskaite, A., Jarasuniene, D., Luksiene, D., Rudys, A., Sakalyte, G., Sliaziene, S., Aguilar-Romero, R., Cardona-Muñoz, E., Castro-Jimenez, J., Chavez-Herrera, J., Chuquiure Valenzuela, E., De la Pena, G., Herrera, E., Leiva-Pons, J., Lopez Alvarado, A., Mendez Machado, G., Ramos-Lopez, G., Basart, D., Buijs, E., Cornel, J., de Leeuw, M., Dijkgraaf, R., Dunselman, P., Freericks, M., Hamraoui, K., Lenderlink, T., Linssen, G., Lodewick, P., Lodewijks, C., Lok, D., Nierop, P., Ronner, E., Somsen, A., van Dantzig, J., van der Burgh, P., van Kempen, L., van Vlies, B., Voors, A., Wardeh, A., Willems, F., Dickstein, K., Gundersen, T., Hole, T., Thalamus, J., Westheim, A., Dabrowski, M., Gorski, J., Korewicki, J., Kuc, K., Miekus, P., Musial, W., Niegowska, J., Piotrowski, W., Podolec, P., Polonski, L., Ponikowski, P., Rynkiewicz, A., Szelemej, R., Trusz-Gluza, M., Ujda, M., Wojciechowski, D, Wysokinski, A., Camacho, A., Fonseca, C., Monteiro, P., Apetrei, E., Bruckner, I., Carasca, E., Coman, I., Datcu, M., Dragulescu, S., Ionescu, P., Iordachescu-Petica, D., Manitiu, I., Popa, V., Pop-Moldovan, A., Radoi, M., Stamate, S., Tomescu, M., Vita, I., Aroutiounov, G., Ballyuzek, M., Bart, B., Churina, S., Glezer, M., Goloshchekin, B., Ivleva, A., Kobalava, Z., Kostenko, V., Lopatin, Y., Martynov, A., Orlov, V., Semernin, E., Shogenov, Z., Sidorenko, B., Skvortsov, A., Storzhakov, G., Sulimov, V., Talibov, O., Tereshenko, S., Tsyrline, V., Zadionchenko, V., Zateyshchikov, D., Dzupina, A., Hranai, M., Kmec, J., Micko, K., Murin, J., Pella, D., Sojka, G., Spisak, V., Vahala, P., Vinanska, D., Badat, A., Bayat, J., Dawood, S., Delport, E., Ellis, G., Garda, R., Klug, E., Mabin, T., Naidoo, D., Pretorius, M., Ranjith, N., Van Zyl, L., Weich, H., Anguita, M., Berrazueta, J., Bruguera i Cortada, J., de Teresa, E., Gómez Sánchez, M., González Juanatey, J., Gonzalez-Maqueda, I., Jordana, R., Lupon, J., Manzano, L., Pascual Figal, D., Pulpón, L., Recio, J., Ridocci Soriano, F., Rodríguez Lambert, J., Roig Minguell, E., Roig Minguell, E., Romero, J., Valdovinos, P., Klintberg, L., Kronvall, T., Lycksell, M., Morner, S., Rydberg, E., Swedberg, K., Timberg, I., Wikstrom, G., Moccetti, T.4, Ashok, J., Banerjee, P., Carr-White, G., Cleland, J., Connolly, E., Francis, M., Greenbaum, R., Kadr, H., Lindsay, S., McMurray, J., Megarry, S., Memon, A., Murdoch, D., Senior, R., Squire, I., Tan, L., Witte, K., Adams, K., Adamson, P., Adler, A., Altschul, L., Altschuller, A., Amirani, H., Anand, I., Andreou, C., Ansari, M., Antonishen, M., Banchs, H., Banerjee, S., Banish, D., Bank, A., Barbagelata, A., Barnard, D., Bellinger, R., Benn, A., Berk, M., Berry, B., Bethala, V., Bilazarian, S., Bisognano, J., Bleyer, F., Blum, M., Boehmer, J., Bouchard, A., Boyle, A., Bozkurt, B., Brown, C., Burlew, B., Burnham, K., Butler, J., Call, J., Cambier, P., Cappola, T., Carlson, R., Chandler, B., Chandra, R., Chandraratna, P., Chernick, R., Colan, D., Colfer, H., Colucci, W., Connelly, T., Costantini, O., Dadkhah, S., Dauber, I., Davis, J., Davis, S., Denning, S., Drazner, M., Dunlap, S., Egbujiobi, L., Elkayam, U., Elliott, J., El-Shahawy, M., Essandoh, L., Ewald, G., Fang, J., Farhoud, H., Felker, G., Fernandez, J., Festin, R., Fishbein, G., Florea, V., Flores, E., Floro, J., Gabris, M., Garg, M., Gatewood, R., Geller, M., Ghali, J., Ghumman, W., Gibbs, G., Gillespie, E., Gilmore, R., Gogia, H., Goldberg, L., Gradus-Pizlo, I., Grainger, T., Gudmundsson, G., Gunawardena, D., Gupta, D., Hack, T., Hall, S., Hamroff, G., Hankins, S., Hanna, M., Hargrove, J., Haught, W., Hauptman, P., Hazelrigg, M., Herzog, C., Heywood, J., Hill, T., Hilton, T., Hirsch, H., Hunter, J., Ibrahim, H., Imburgia, M., Iteld, B., Jackson, B., Jaffrani, N., Jain, D., Jain, A., James, M., Jimenez, J., Johnson, E., Kale, P., Kaneshige, A., Kapadia, S., Karia, D., Karlsberg, R., Katholi, R., Kerut, E., Khoury, W., Kipperman, R., Klapholz, M., Kosinski, E., Kozinn, M., Kraus, D., Krueger, S., Krum, H., Kumar, S., Lader, E., Lee, C., Levy, W., Lewis, E., Light-McGroary, K., Loh, I., Lombardi, W., Machado, C., Maislos, F., Mancini, D., Markus, T., Mather, P., McCants, K., McGrew, F., McLaurin, B., McMillan, E., McNamara, D., Meyer, T., Meymandi, S., Miller, A., Minami, E., Modi, M., Mody, F., Mohanty, P., Moscoso, R., Moskowitz, R., Moustafa, M., Mullen, M., Naz, T., Noonan, T., OʼBrien, T., Oellerich, W., Oren, R., Pamboukian, S., Pereira, N., Pitt, W., Porter, C., Prabhu, S., Promisloff, S., Ratkovec, R., Richardson, R., Ross, A., Saleh, N., Saltzberg, M., Sarkar, S., Schmedtje, J., Schneider, R., Schuyler, G., Shanes, J., Sharma, A., Siegel, C., Siegel, R., Silber, D., Singh, V., Singh, N., Singh, J., Sklar, J., Small, R., Smith, A., Smith, E., Smith, E., Smull, D., Sotolongo, R., Staniloae, C., Stapleton, D., Steele, P., Stehlik, J., Stein, M., Tang, W., Thadani, U., Torre-Amoine, G., Trichon, B., Tsai, C., Tummala, R., Van Bakel, A., Vicari, R., Vijay, N., Vijayaraghavan, K., Vittorio, T., Vossler, M., Wagoner, L., Wallis, D., Ward, N., Widmer, M., Wight, J., Wilkins, C., Williams, C., Williams, G., Winchester, M., Winkel, E., Wittmer, B., Wood, D., Wormer, D., Wright, R., Xu, Z., Yasin, M., and Zolty, R.
- Published
- 2013
- Full Text
- View/download PDF
10. TCF7L2 Polymorphisms are Associated with Type 2 Diabetes in Khatri Sikhs from North India: Genetic Variation Affects Lipid Levels
- Author
-
Sanghera, D. K., Nath, S. K., Ortega, L., Gambarelli, M., Kim-Howard, X., Singh, J. R., Ralhan, S. K., Wander, G. S., Mehra, N. K., Mulvihill, J. J., and Kamboh, M. I.
- Published
- 2008
11. Preliminary study of non-psychotic disorders in people from the Indian subcontinent living in the UK and India
- Author
-
Creed, F., Winterbottom, M., Tomenson, B., Britt, R., Anand, I. S., Wander, G. S., and Chandrashekhar, Y.
- Published
- 1999
12. Self-blood pressure measurement as compared to office blood pressure measurement in a large Indian population; the India Heart Study.
- Author
-
Kaul, Upendra, Wander, G. S., Sinha, Nakul, Mohan, Jagdish C., Kumar, Soumitra, Dani, Sameer, Ponde, Chandrashekhar K., Pinto, Brian, Dalal, Jamshed, Hiremath, Jagdish, Kapoor, Sunil, Baruah, D. K., Nair, Tiny, Alexander, Thomas, Mohan, Viswanathan, Joshi, Shashank, Sivakadaksham, N., Omboni, Stefano, Arambam, Priyadarshini, and Suvarna, Viraj
- Published
- 2020
- Full Text
- View/download PDF
13. Traditional Indian practices: Time to revisit and re-adopt for a healthier lifestyle.
- Author
-
Tyagi, Ruchita, Gupta, Vivek, Kumar, Rajiv, and Wander, G
- Subjects
SOCIAL distancing ,COVID-19 pandemic ,FOOD habits ,MEDICAL technology ,INFECTIOUS disease transmission ,PANDEMICS - Abstract
The COVID-19 pandemic has affected human life significantly. In spite of significant advancement of medical technology, management is still focused on preventive strategies due to non availability of vaccine or any definitive treatment. The preventive strategies include hand hygiene, social distancing, isolation/quarantine along with the methods for boosting immunity. The ancient literature and several traditional practices of our country guide a hygienic life style and address several preventive aspects of transmission of infection across the society. Furthermore, healthy eating habits and use of various herbs and spices as regular food ingredients has been proven for boosting the immunity. In this review, we have tried to correlate the traditional practices with the available scientific evidences. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Negative pressure aerosol containment box: An innovation to reduce COVID-19 infection risk in healthcare workers.
- Author
-
Gupta, Vivek, Sahani, Ashish, Mohan, Bishav, and Wander, G
- Subjects
COVID-19 ,AEROSOLS ,VIRUS diseases ,INTENSIVE care units ,NASAL cannula - Abstract
Healthcare workers (HCW's) are at increased risk of corona virus disease (COVID-19) infection during aerosol generating activities. The aerosol box has been used during intubation and extubation to prevent transmission of infection to HCWs. Isolation room with negative pressure has been advocated for COVID-19 patients. The described containment box has been designed to be useful in COVID intensive care unit (ICU) as a multipurpose box which is a cost effective and readily available resource. This innovation combines the containment box with negative pressure generation using central vacuum [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Application of Genetic Algorithms to the Online Tuning of Electric Drive Speed Controllers
- Author
-
da Silva, Wander G., Acarnley, Paul P., and Finch, John W.
- Subjects
Genetic algorithms -- Usage ,Tuning (Electronics) -- Methods ,Electric controllers -- Models ,Business ,Computers ,Electronics ,Electronics and electrical industries - Abstract
Tuning of electric drive speed controllers is complicated by nonlinearities. Usual practice obtains controller settings with conventional linear analysis methods and then tunes the settings using trial-and-error methods during commissioning. An alternative approach, using genetic algorithms for the online tuning, is proved experimentally to optimize the drive's response efficiently. These settings are critically dependent on operating point. Index Terms--Electric drives, genetic algorithms, speed control, tuning.
- Published
- 2000
16. Troubleshooting in geoelectrical prospecting using real-coded genetic algorithm with chromosomal extrapolation.
- Author
-
Calixto, Wesley Pacheco, Paulo Coimbra, A., Mota, Jesus Carlos da, Wu, Marcel, Silva, Wander G., Alvarenga, Bernardo, Brito, Leonardo da Cunha, Alves, Aylton Jose, Domingues, Elder Geraldo, and Neto, Daywes Pinheiro
- Subjects
GENETIC algorithms ,ELECTRIC prospecting ,EXTRAPOLATION ,MATHEMATICAL models ,MATHEMATICAL optimization ,ELECTRIC networks - Abstract
SUMMARY This work presents a genetic operator developed from mathematical methods of curve extrapolation applied in solving problems in geoelectrical prospection. This operator will assist the production of fitter individuals in the population of a genetic algorithm in which inherent patterns of the best individuals of each generation are recognized. The proposed operator in conjunction with a real-coded genetic algorithm is compared to five alternative optimization techniques known and used in the application to problems in geoelectrical prospection. Copyright © 2014 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
17. Anti-symmetric rank-two tensor matter field on superspace for NT=2
- Author
-
Spalenza, Wesley, Ney, Wander G, and Helayel-Neto, J.A
- Published
- 2004
- Full Text
- View/download PDF
18. Carter's factor calculation using domain transformations and the finite element method.
- Author
-
Calixto, Wesley Pacheco, Alvarenga, Bernardo, Coimbra, A. Paulo, Alves, Aylton Jose, Martins Neto, Luciano, Wu, Marcel, Silva, Wander G., and Delbone, Edval
- Subjects
FINITE element method ,MATHEMATICAL transformations ,METHODOLOGY ,ENERGY bands ,NUMERICAL analysis ,FACTOR analysis - Abstract
SUMMARY The main purpose of this work is to present a methodology to calculate Carter's factor using the actual air-gap geometry, that is, without simplifications of the slot geometry. The methodology is based on the finite element method, and its results are compared with some traditional procedures used for Carter's factor calculation and also with a domain transformation technique. It is shown that the finite element method and the domain transformation methodologies present similar results, which are different from the results obtained with traditional procedures. Copyright © 2011 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. Blood component therapy: Which, when and how much.
- Author
-
Arya, Rajesh Chand, Wander, G. S., and Gupta, Pankaj
- Subjects
- *
BLOOD transfusion , *BLOOD products , *CLINICAL trials , *HEMORRHAGE , *BLOOD coagulation - Abstract
Blood transfusion refers to the perioperative administration of blood and blood components. Adherence to proper indications for blood component therapy is essential because of its potential adverse effects and costs of transfusion. Over the years, the significance of blood components in treating certain diseases or conditions has been recognized. In this article, the most commonly used blood components along with the new developments in component therapy have been discussed. Recommendations by different academic and clinical trials and studies have been presented for quick reference. The individual coagulation factors are discussed in brief. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
20. Modeling and Analysis of Piezoelectric Energy Harvesting From Aeroelastic Vibrations Using the Doublet-Lattice Method.
- Author
-
De Marqui Jr., Carlos, Vieira, Wander G. R., Erturk, Alper, and Inman, Daniel J.
- Subjects
PIEZOELECTRIC ceramics ,ENERGY harvesting ,MECHANICAL vibration research ,ELECTRIC circuits ,AERODYNAMICS - Abstract
Multifunctional structures are pointed out as an important technology for the design of aircraft with volume, mass, and energy source limitations such as unmanned air vehicles (UAVs) and micro air vehicles (MAVs). In addition to its primary function of bearing aerodynamic loads, the wing/spar structure of an UAV or a MAV with embedded piezoceramics can provide an extra electrical energy source based on the concept of vibration energy harvesting to power small and wireless electronic components. Aeroelastic vibrations of a lifting surface can be converted into electricity using piezoelectric transduction. In this paper frequency-domain piezoaeroelastic modeling and analysis of a cantilevered platelike wing with embedded piezoceramics is presented for energy harvesting. The electromechanical finite-element plate model is based on the thin-plate (Kirchhoff) assumptions while the unsteady aerodynamic model uses the doublet-lattice method. The electromechanical and aerodynamic models are combined to obtain the piezoaeroelastic equations, which are solved using a p-k scheme that accounts for the electromechanical coupling. The evolution of the aerodynamic damping and the frequency of each mode are obtained with changing airflow speed for a given electrical circuit. Expressions for piezoaeroelastically coupled frequency response functions (voltage, current, and electrical power as well the vibratory motion) are also defined by combining flow excitation with harmonic base excitation. Hence, piezoaeroelastic evolution can be investigated in frequency domain for different airflow speeds and electrical boundary conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
21. Hemodynamic Effects of Arteriovenous Fistula in End-Stage Renal Failure.
- Author
-
Sandhu, J. S., Wander, G. S., Gupta, M. L., Aulakh, B. S., Nayyar, A. K., and Sandhu, P.
- Subjects
- *
ARTERIOVENOUS fistula , *CHRONIC kidney failure , *CHRONIC diseases , *KIDNEY diseases , *HEMODYNAMICS - Abstract
Hemodynamic parameters using Swan Ganz catheter were studied in 17 patients with end stage renal disease. The acute effects of radiocephalic AV fistula on the hemodynamic parameters were studied at 24 hours of surgery. The chronic effects were studied in 8 of these patients at 6 weeks of arteriovenous(AV) fistula. The AV fistula matured in 3 to 4 weeks time and blood flow was sufficient for hemodialysis(400 mL/min). Patients with chronic renal failure had normal or high normal hemodynamic parameters. Six weeks after the AV fistula, the cardiac index and the stroke volume index slightly increased along with a significant increase in systolic and mean systemic arterial pressure. None of the patients had significant increase in cardiac filling pressures. Although there was some fall in systemic vascular resistance index and rise in cardiac index and stroke volume index, these changes were physically small and unlikely to put any extra hemodynamic load. Thus, AV fistula in dialysis patients is not an appreciable cause of circulatory or pulmonary congestion. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
22. Anti-symmetric rank-two tensor matter field on superspace for <f>NT=2</f>
- Author
-
Spalenza, Wesley, Ney, Wander G., and Helayel-Neto, J.A.
- Abstract
In this work, we discuss the interaction between anti-symmetric rank-two tensor matter and topological Yang–Mills fields. The matter field considered here is the rank-2 Avdeev–Chizhov tensor matter field in a suitably extended
NT=2 SUSY. We start off from theNT=2 ,D=4 superspace formulation and we go over to Riemannian manifolds. The matter field is coupled to the topological Yang–Mills field. We show that both actions are obtained asQ -exact forms, which allows us to express the energy–momentum tensor asQ -exact observables. [Copyright &y& Elsevier]- Published
- 2004
- Full Text
- View/download PDF
23. Über das 'Hesperidin'︁ einiger Pflanzen.
- Author
-
Oesterle, O. A. and Wander, G.
- Published
- 1925
- Full Text
- View/download PDF
24. Interaction between humic substances and arsenic species simulating environmental conditions.
- Author
-
Costa, Aryanna S.P.N., Nascimento, Amanda L.A., Botero, Wander G., Carvalho, Cenira M., Tonholo, Josealdo, Santos, Josué C.C., and Anunciação, Daniela S.
- Published
- 2022
- Full Text
- View/download PDF
25. The effect of a single dose of kava and midazolam on emergence time from general anesthesia following an abdominal surgical procedure in the male Sprague-Dawley rat (Rattus norvegicus)
- Author
-
Ellis JA, Spanton JL, Wander G, Reilly M, and Johnson AD
- Published
- 2007
26. Pregnancy in women with a Fontan circulation: Short and long-term outcomes.
- Author
-
Breviario S, Krishnathasan K, Dimopoulos K, Gribaudo E, Constantine A, Li W, Kewada D, Patel D, Wander G, Patel RR, Johnson MR, Gatzoulis MA, Montanaro C, and Rafiq I
- Subjects
- Humans, Female, Pregnancy, Retrospective Studies, Adult, Follow-Up Studies, Young Adult, Infant, Newborn, Heart Defects, Congenital surgery, Time Factors, Fontan Procedure adverse effects, Fontan Procedure trends, Pregnancy Outcome epidemiology, Pregnancy Complications, Cardiovascular epidemiology
- Abstract
Background: The Fontan circulation procedure is the palliative surgery of choice for patients with single ventricle physiology, many of whom are now reaching childbearing age due to advances in care. Our study examines the impact of pregnancy on women with Fontan circulation, assessing both short and long-term outcomes., Methods: We retrospectively analysed pregnancies in women with Fontan circulation at our centre from 2005 to 2023, including a matched non-pregnant, nulliparous cohort for comparison. Pregnancies lost before 18 weeks were analysed separately., Results: Among 26 pregnancies in 18 women, preterm births were common (73.1%), with 3 fetal losses and no maternal deaths. Neonatal complications included a 50% incidence of babies small for gestational age (SGA). Cardiac events occurred in 19.2% of pregnancies, primarily supraventricular arrhythmias, and 23% experienced postpartum haemorrhage. Over a median 6.1 [5.2-10.6]-year follow-up, no deaths, heart failure (HF), or Fontan-associated liver disease (FALD) developed, and functional status remained stable., Conclusions: Women with a Fontan-type circulation undergoing pregnancy had a few serious maternal cardiac events, though there was a high rate of post-partum haemorrhage. The rates of neonatal complications, particularly related to restricted growth and pre-term birth, were also high. Our findings indicate a generally positive medium-term outlook for these patients, though the impact of pregnancy on long-term survival remains unclear. Careful selection of patients with Fontan circulation during pre-pregnancy counselling may help to reduce complications during and after pregnancy., Competing Interests: Declaration of competing interest Dr. Krishnathasan and Dr. Constantine have received educational grants, personal fees and non-financial support from Jannsen-Cilag Limited. Professor Dimopoulos has received nonfinancial support from Jannsen-Cilag Limited and has been a consultant to and received grants and personal fees from Jannsen-Cilag Limited, Pfizer, GlaxoSmithKline, and Bayer/MSD. All the remaining authors have no relationships with industry to declare., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
27. Pregnancy in patients with the Fontan operation.
- Author
-
Montanaro C, Boyle S, Wander G, Johnson MR, Roos-Hesselink JW, Patel R, Rafiq I, Silversides CK, and Gatzoulis MA
- Subjects
- Humans, Female, Pregnancy, Pregnancy Outcome, Risk Factors, Treatment Outcome, Risk Assessment, Fontan Procedure adverse effects, Pregnancy Complications, Cardiovascular physiopathology, Heart Defects, Congenital surgery, Heart Defects, Congenital physiopathology
- Abstract
Improved survival rates for patients with a Fontan circulation has allowed more women with this complex cardiac physiology to contemplate pregnancy. However, pregnancy in women with a Fontan circulation is associated with a high risk of adverse maternal and foetal outcomes, high rates of miscarriage, and preterm delivery. Factors associated with a successful pregnancy outcome are younger age, normal body weight, absence of significant functional limitation, no Fontan-related complications, and well-functioning single ventricle physiology. Appropriate care with timely preconception counselling and regular, frequent clinical reviews by a multidisciplinary team based at a tertiary centre improves the chance of a successful pregnancy. Empowerment of patients with education on their specific congenital cardiac condition and its projected trajectory helps them make informed choices regarding their health, reproductive choices, and assists them to achieve their life goals., Competing Interests: Conflict of interest: none declared., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
28. Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease.
- Author
-
Chopra HK, Khullar D, Nair T, Wander GS, Ponde CK, Ray S, Nanda NC, Kasliwal RR, Rana DS, Kirpalani A, Sawhney J, Chandra P, Mehta Y, Kumar V, Tewari S, Pancholia AK, Kher V, Bansal S, Mittal S, Kerkar P, Sahoo PK, Hotchandani R, Prakash S, Chauhan N, Rastogi V, Jabir A, Shanmugasundaram S, Tiwaskar M, Sinha A, Gupta V, Mishra SS, Routray SN, Omar AK, Swami OC, Jaswal A, Alam S, Passey R, Rajput R, Paul J, Kapoor A, Prabhakar D, Chandra S, Malhotra P, Singh VP, Bansal M, Shah P, Jain S, Bhargava M, Vijayalakshmi IB, Varghaese K, Jain D, Goel A, Gaur N, Tandon R, Moorthy A, George S, Katyal VK, Mantri RR, Mehrotra R, Bhalla D, Mittal V, Rao S, Jagia M, Singh H, Awasthi S, Sattur A, Mishra R, Pandey A, Chawla R, Jaggi S, Sehgal B, Sehgal A, Goel N, Gupta R, Kubba S, Chhabra A, Bagga S, and Shastry NR
- Subjects
- Humans, India epidemiology, Consensus, Adrenergic beta-1 Receptor Antagonists therapeutic use, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic drug therapy, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Bisoprolol therapeutic use, Angiotensin Receptor Antagonists therapeutic use
- Abstract
Chronic kidney disease (CKD) is a major contributor to morbidity and mortality in India. CKD often coexists with heart failure (HF), diabetes, and hypertension. All these comorbidities are risk factors for renal impairment. HF and CKD are pathophysiologically intertwined, and the deterioration of one can worsen the prognosis of the other. There is a need for safe renal pharmacological therapies that target both CKD and HF and are also useful in hypertension and diabetes. Neurohormonal activation achieved through the activation of the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS), and the natriuretic peptide system (NPS) is fundamental in the pathogenesis and progression of CKD and HF. Angiotensin receptor neprilysin inhibitor (ARNi), sodium-glucose cotransporter 2 inhibitors (SGLT-2i), and selective β1-blocker (B1B) bisoprolol suppress this neurohormonal activation. They also have many other cardiorenal benefits across a wide range of CKD patients with or without concomitant HF, diabetes, or hypertension. This consensus statement from India explores the place of ARNi, SGLT-2i, and bisoprolol in the management of CKD patients with or without HF and other comorbidities., (© Journal of the Association of Physicians of India 2024.)
- Published
- 2024
- Full Text
- View/download PDF
29. Current Place of SGLT2i in the Management of Heart Failure: An Expert Opinion from India.
- Author
-
Chopra HK, Nair T, Wander GS, Ponde CK, Ray S, Khullar D, Nanda NC, Narula J, Kasliwal RR, Rana DS, Kirpalani A, Sawhney JPS, Chandra P, Mehta Y, Kumar V, Tewari S, Pancholia AK, Kher V, Bansal S, Mittal S, Kerkar P, Sahoo PK, Hotchandani R, Prakash S, Chauhan N, Rastogi V, Jabir A, Shanmugasundaram S, Tiwaskar M, Sinha A, Gupta V, Mishra SS, Routray SN, Omar AK, Swami OC, Jaswal A, Alam S, Passey R, Rajput R, Paul J, Kapoor A, Prabhakar D, Chandra S, Malhotra P, Singh VP, Bansal M, Shah P, Jain S, Bhargava M, Vijayalakshmi IB, Varghaese K, Jain D, Goel A, Mehmood K, Gaur N, Tandon R, Moorthy A, George S, Katyal VK, Mantri RR, Mehrotra R, Bhalla D, Mittal V, Rao S, Jagia M, Singh H, Awasthi S, Sattur A, Mishra R, Pandey A, Chawla R, Jaggi S, Sehgal B, Sehgal A, Goel N, Gupta R, Kubba S, Chhabra A, Bagga S, and Shastry NR
- Subjects
- Humans, India, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Heart Failure drug therapy, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 complications
- Abstract
Heart failure (HF) is a global health concern that is prevalent in India as well. HF is reported at a younger age in Indian patients with comorbidity of type 2 diabetes (T2DM) in approximately 50% of patients. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), originally approved for T2DM, are new guideline-recommended and approved treatment strategies for HF. Extensive evidence highlights that SGLT2i exhibits profound cardiovascular (CV) benefits beyond glycemic control. SGLT2i, in conjunction with other guideline-directed medical therapies (GMDT), has additive effects in improving heart function and reducing adverse HF outcomes. The benefits of SGLT2i are across a spectrum of patients, with and without diabetes, suggesting their potential place in broader HF populations irrespective of ejection fraction (EF). This consensus builds on the updated evidence of the efficacy and safety of SGLT2i in HF and recommends its place in therapy with a focus on Indian patients with HF., (© Journal of the Association of Physicians of India 2024.)
- Published
- 2024
- Full Text
- View/download PDF
30. Multifaceted Fontan Patients and Their Response to Pregnancy.
- Author
-
Wander G, Breviario S, Krishnathasan K, Patel RR, Habibi H, Li W, Johnson MR, Gatzoulis MA, Dimopoulos K, and Rafiq I
- Abstract
We present 4 patients with Fontan circulation who underwent successful pregnancies, albeit with complications that required close monitoring and timely intervention. Each Fontan patient presents with a unique clinical picture, making risk stratification challenging but all the more important., Competing Interests: The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
31. Role of Bisoprolol in Heart Failure Management: A Consensus Statement from India.
- Author
-
Chopra HK, Nair T, Wander GS, Ponde CK, Ray S, Khullar D, Nanda NC, Kasliwal RR, Rana DS, Kirpalani A, Sawhney JPS, Chandra P, Mehta Y, Kumar V, Tewari S, Pancholia AK, Kher V, Bansal S, Mittal S, Kerkar P, Sahoo PK, Hotchandani R, Prakash S, Chauhan N, Rastogi V, Jabir A, Shanmugasundaram S, Tiwaskar M, Sinha A, Gupta V, Mishra SS, Routray SN, Omar AK, Swami OC, Jaswal A, Alam S, Passey R, Rajput R, Paul J, Kapoor A, Prabhakar D, Chandra S, Malhotra P, Singh VP, Bansal M, Shah P, Jain S, Bhargava M, Vijayalakshmi IB, Varghaese K, Jain D, Goel A, Gaur N, Tandon R, Moorthy A, George S, Katyal VK, Mantri RR, Mehrotra R, Bhalla D, Mittal V, Rao S, Jagia M, Singh H, Awasthi S, Sattur A, Mishra R, Pandey A, Chawla R, Jaggi S, Sehgal B, Sehgal A, Goel N, Gupta R, Kubba S, Chhabra A, Bagga S, and Shastry NR
- Subjects
- Humans, India, Consensus, Bisoprolol therapeutic use, Heart Failure drug therapy, Adrenergic beta-1 Receptor Antagonists therapeutic use
- Abstract
In India, heart failure (HF) is an important health concern affecting younger age groups than the western population. A limited number of Indian patients receive guideline-directed medical therapy (GDMT). Selective β-1 blockers (BB) are one of the GDMTs in HF and play an important role by decreasing the sympathetic overdrive. The BB reduces heart rate (HR) reverse the adverse cardiac (both ventricular and atrial), vascular, and renovascular remodeling seen in HF. Bisoprolol, a β-1 blocker, has several advantages and can be used across a wide spectrum of HF presentations and in patients with HF and comorbid conditions such as coronary artery disease (CAD), atrial fibrillation (AF), post-myocardial infarction (MI), uncontrolled diabetes, uncontrolled hypertension, and renal impairment. Despite its advantages, bisoprolol is not optimally utilized for managing HF in India. This consensus builds on updated evidence on the efficacy and safety of bisoprolol in HF and recommends its place in therapy with a focus on Indian patients with HF., (© Journal of the Association of Physicians of India 2023.)
- Published
- 2023
- Full Text
- View/download PDF
32. Direct current cardioversion in pregnancy: a multicentre study.
- Author
-
Cauldwell M, Adamson D, Bhatia K, Bhagra C, Bolger A, Everett T, Fox C, Girling J, Head C, English K, Hudsmith L, James R, Johnson M, MacKiliop L, McAuliffe FM, Mariappa G, Orchard E, O'Brien M, Siddiqui F, Simpson L, Simpson M, Timmons P, Vause S, Wander G, Walker N, and Steer PJ
- Subjects
- Humans, Female, Pregnancy, Electric Countershock, Treatment Outcome, Retrospective Studies, Atrial Fibrillation, Heart Diseases
- Abstract
Objective: Direct current cardioversion (DCCV) in pregnancy is rarely required and typically only documented in single case reports or case series. A recent UK confidential enquiry reported on several maternal deaths where appropriate DCCV appeared to have been withheld., Design: Retrospective cohort study., Setting: Seventeen UK and Ireland specialist maternity centres., Sample: Twenty-seven pregnant women requiring DCCV in pregnancy., Main Outcome Measures: Maternal and fetal outcomes following DCCV., Results: Twenty-seven women had a total of 29 DCCVs in pregnancy. Of these, 19 (70%) initial presentations were to Emergency Departments and eight (30%) to maternity settings. There were no maternal deaths. Seventeen of the women (63%) had a prior history of heart disease. Median gestation at DCCV was 28 weeks, median gestation at delivery was 35 weeks, with a live birth in all cases. The abnormal heart rhythms documented at the first cardioversion were atrial fibrillation in 12/27 (44%) cases, atrial flutter in 8/27 (30%), supraventricular tachycardia in 5/27 (19%) and atrial tachycardia in 2/27 (7%). Fetal monitoring was undertaken following DCCV on 14/29 (48%) occasions (10 of 19 (53%) at ≥26 weeks) and on 2/29 (7%) occasions, urgent delivery was required post DCCV., Conclusions: Direct current cardioversion in pregnancy is rarely required but should be undertaken when clinically indicated according to standard algorithms to optimise maternal wellbeing. Once the woman is stable post DCCV, gestation-relevant fetal monitoring should be undertaken. Maternity units should develop multidisciplinary processes to ensure pregnant women receive the same standard of care as their non-pregnant counterparts., (© 2023 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
33. Role of two-dimensional strain echocardiographic parameters in suspected acute coronary syndrome patients with initial non-diagnostic electrocardiogram and troponins: An observational study.
- Author
-
Tandon R, Singal G, Chand Arya R, Sachdeva S, Goyal A, Takkar Chhabra S, Aslam N, Singh Wander G, Mohan B, and Batta A
- Subjects
- Humans, Troponin, ROC Curve, Echocardiography methods, Electrocardiography methods, Ventricular Function, Left, Reproducibility of Results, Acute Coronary Syndrome diagnostic imaging, Coronary Artery Disease
- Abstract
Introduction: Diagnosis of acute coronary syndrome (ACS) is often challenging especially in presence of initial normal troponins and non-specific electrocardiogram. The index study aimed at determining the diagnostic value of strain echocardiography in patients with suspected ACS but with non-diagnostic electrocardiogram and echocardiography findings., Methods: The study was conducted on 42 patients with suspected ACS and non-diagnostic electrocardiograms, normal quantitative troponin-T levels, and left ventricular function. All patients underwent conventional and 2D-strain echocardiography followed by coronary angiography, within 24 h of admission. Patients with regional wall motion abnormalities (RWMA), valvular heart disease, suspected myocarditis, and past coronary artery disease (CAD) were excluded., Results: Amongst the global strains, the global circumferential strain (GCS) was significantly reduced (p = .014) amongst those with significant CAD on angiography as opposed to global longitudinal strain (GLS) which was similar in the two groups (p = .33). The GCS/GLS ratio was also significantly reduced in patients with significant CAD compared to those with normal/mild disease on coronary angiography (p = .025). Both the parameters had good accuracy in predicting significant CAD. GCS displayed a sensitivity of 80% and a specificity of 86% at an optimal cut-off 31.5% (AUROC: .93, 95% CI: .601-1.000; p = .03), and likewise GCS/GLS ratio had a sensitivity of 80% and a specificity and 86% at a cut-off of 1.89% (AUROC: .86, 95% CI: .592-1.000; p = .049). GLS and peak atrial longitudinal strain (PALS) did not differ significantly in patients with/without significant CAD (p = .32 and .58, respectively)., Conclusion: GCS and GCS/GLS ratio provides incremental value in comparison to GLS, PALS, and tissue Doppler indices (E/e') in patients with suspected ACS and non-diagnostic electrocardiogram and troponins. GCS at cut-off of >31.5% and GCS/GLS ratio >1.89 can reliably exclude patients with significant CAD in this setting., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
34. Pregnancy in women with congenital heart disease: a focus on management and preventing the risk of complications.
- Author
-
Wander G, van der Zande JA, Patel RR, Johnson MR, and Roos-Hesselink J
- Subjects
- Adult, Child, Pregnancy, Female, Humans, Risk Factors, Prognosis, Pregnancy Complications, Cardiovascular prevention & control, Heart Defects, Congenital complications, Heart Defects, Congenital therapy, Eisenmenger Complex complications
- Abstract
Introduction: Congenital heart disease (CHD) is the most common cardiac disorder in pregnancy in the western world (around 80%). Due to improvements in surgical interventions more women with CHD are surviving to adulthood and choosing to become pregnant., Areas Covered: Preconception counseling, antenatal management of CHDs and strategies to prevent maternal and fetal complications.Preconception counseling should start early, before the transition to adult care and be offered to both men and women. It should include the choice of contraception, lifestyle modifications, pre-pregnancy optimization of cardiac state, the chance of the child inheriting a similar cardiac lesion, the risks to the mother, and long-term prognosis. Pregnancy induces marked physiological changes in the cardiovascular system that may precipitate cardiac complications. Risk stratification is based on the underlying cardiac disease and data from studies including CARPREG, ZAHARA, and ROPAC., Expert Opinion: Women with left to right shunts, regurgitant lesions, and most corrected CHDs are at lower risk and can be managed in secondary care. Complex CHD, including systemic right ventricle need expert counseling in a tertiary center. Those with severe stenotic lesions, pulmonary artery hypertension, and Eisenmenger's syndrome should avoid pregnancy, be given effective contraception and managed in a tertiary center if pregnancy does happen.
- Published
- 2023
- Full Text
- View/download PDF
35. Angiotensin Receptor-Neprilysin Inhibitor Therapy and Cardiac Remodeling in Heart Failure: Consensus Statement from India.
- Author
-
Chopra HK, Wander GS, Nair T, Ponde CK, Nanda NC, Narula J, Ray S, Venugopal K, Iyengar SS, Kasliwal RR, Chandra P, Prakash S, Bansal S, Rana DS, Kerkar P, Dasbiswas A, Sawhney J, Shanmungasundram S, Kumar V, Vijayalakshmi IB, Pancholia AK, Sharma V, Kapoor A, Swami OC, Isser HS, Rastogi V, Arora YK, Omar AK, Sathe S, Rajput R, Prabhakar D, Paul GJ, Jagia P, Malhotra P, Suryaprakash G, Mittal V, Jagia M, Jabir A, Mishra SS, Routray SN, Sinha AK, Bhargava M, Mahmood K, Lal S, Dabhade D, Bhatia M, Kalra P, Katyal VK, Tandon R, Grover R, Chhabra A, and Shastry NR
- Subjects
- Humans, Ventricular Remodeling, Tetrazoles pharmacology, Treatment Outcome, Angiotensin Receptor Antagonists therapeutic use, Stroke Volume, Antihypertensive Agents, Neprilysin pharmacology, Heart Failure drug therapy, Heart Failure diagnosis
- Abstract
Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR)., (© Journal of the Association of Physicians of India 2011.)
- Published
- 2023
36. Role of Iron Therapy in Heart Failure: A Consensus Statement from India.
- Author
-
Chopra HK, Wander GS, Nair T, Ponde CK, Nanda NC, Narula J, Ray S, Venugopal K, Iyengar SS, Kasliwal RR, Chandra P, Prakash S, Bansal S, Rana DS, Kerkar P, Dasbiswas A, Sawhney J, Shanmungasundram S, Kumar V, Vijayalakshmi IB, Pancholia AK, Sharma V, Kapoor A, Swami OC, Isser HS, Rastogi V, Arora YK, Omar AK, Sathe S, Rajput R, Prabhakar D, Paul GJ, Jagia P, Malhotra P, Suryaprakash G, Mittal V, Jagia M, Jabir A, Mishra SS, Routray SN, Sinha AK, Bhargava M, Mahmood K, Bhatia M, Kalra P, Katyal VK, Tandon R, Grover R, Chhabra A, and Shastry NR
- Subjects
- Humans, Quality of Life, Iron therapeutic use, Anemia, Iron-Deficiency etiology, Anemia, Iron-Deficiency complications, Iron Deficiencies, Heart Failure complications, Heart Failure drug therapy
- Abstract
Iron deficiency (ID) with or without anemia is frequently observed in patients with heart failure (HF). Uncorrected ID is associated with higher hospitalization and mortality in patients with acute HF (AHF) and chronic HF (CHF). Hence, in addition to chronic renal insufficiency, anemia, and diabetes, ID appears as a novel comorbidity and a treatment target of CHF. Intravenous (IV) ferric carboxymaltose (FCM) reduces the hospitalization risk due to HF worsening and improves functional capacity and quality of life (QOL) in HF patients. The current consensus document provides criteria, an expert opinion on the diagnosis of ID in HF, patient profiles for IV FCM, and correct administration and monitoring of such patients., (© Journal of the Association of Physicians of India 2011.)
- Published
- 2023
- Full Text
- View/download PDF
37. The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement.
- Author
-
Chopra HK, Wander GS, Ponde CK, Nanda NC, Khullar D, Venugopal K, Ray S, Nair T, Rana DS, Kher V, S Sawhney JP, Kasliwa RR, Jabir A, Chakraborty R, Chandra P, Bansal S, Kumar V, Pancholia AK, Kapoor A, Prakash S, Saxena A, Rastogi V, Sharma V, Arora YK, Dasbiswas A, Bhargava M, Jaswal A, Bhargava K, Bhatia M, Omar AK, Khanna NN, Passey R, Bhalla D, Vijayalakshmi IB, Bhalla AK, Moorthy A, Isser HS, Mishra SS, Routray SN, Tandon V, Sinha A, Bansal M, Jain P, Hotchandani R, Jain D, Katyal VK, Gulati S, Tandon R, Jaggi S, Sehgal B, Gupta V, Mehrotra R, Krishnamani NC, Pathak SN, Yadav MS, Chawla R, Pal J, Chatterjee N, Samajdar SS, and Shastry NR
- Subjects
- Humans, Neprilysin pharmacology, Stroke Volume physiology, Tetrazoles therapeutic use, Tetrazoles pharmacology, Quality of Life, Ventricular Function, Left, Angiotensin Receptor Antagonists therapeutic use, Angiotensin Receptor Antagonists pharmacology, Treatment Outcome, Antihypertensive Agents therapeutic use, Drug Combinations, Heart Failure drug therapy
- Abstract
;Heart failure (HF) is a huge global public health task due to morbidity, mortality, disturbed quality of life, and major economic burden. It is an area of active research and newer treatment strategies are evolving. Recently angiotensin receptor-neprilysin inhibitor (ARNI), a class of drugs (the first agent in this class, Sacubitril-Valsartan), reduces cardiovascular mortality and morbidity in chronic HF patients with reduced left ventricular ejection fraction (LVEF). Positive therapeutic effects have led to a decrease in cardiovascular mortality and HF hospitalizations (HFH), with a favorable safety profile, and have been documented in several clinical studies with an unquestionable survival benefit with ARNI, Sacubitril-Valsartan. This consensus statement of the Indian group of experts in cardiology, nephrology, and diabetes provides a comprehensive review of the power and promise of ARNI in HF management and an evidence-based appraisal of the use of ARNI as an essential treatment strategy for HF patients in clinical practice. Consensus in this review favors an early utility of Sacubitril-Valsartan in patients with HF with reduced EF (HFrEF), regardless of the previous therapy being given. A lower rate of hospitalizations for HF with Sacubitril-Valsartan in HF patients with preserved EF who are phenotypically heterogeneous suggests possible benefits of ARNI in patients having 40-50% of LVEF, frequent subtle systolic dysfunction, and higher hospitalization risk., (© Journal of the Association of Physicians of India 2011.)
- Published
- 2023
- Full Text
- View/download PDF
38. Heart Failure with Preserved Ejection Fraction: Management Guidelines (From Heart Failure Association of India, Endorsed by Association of Physicians of India).
- Author
-
S H, Oomman A, Jadhav UM, Raghuraman B, Mohanan PP, Tiwaskar M, Wander GS, and Chopra VK
- Subjects
- Aminobutyrates, Angiotensin Receptor Antagonists therapeutic use, Biphenyl Compounds, Drug Combinations, Humans, Stroke Volume, Tetrazoles adverse effects, Heart Failure diagnosis, Heart Failure drug therapy, Physicians, Sodium-Glucose Transporter 2 Inhibitors therapeutic use
- Abstract
Heart failure with preserved ejection fraction (HFpEF) accounts for 15-20% of patients with heart failure (HF) in India. Diagnosis is by clinical features supported by biomarkers and echocardiography. Lifestyle modifications, control of risk factors to optimum levels, and treatment of comorbidities are essential in the management of HFpEF. Spironolactone and sacubitril-valsartan [angiotensin receptor neprilysin inhibitor (ARNI)] are beneficial in subsets of HFpEF, especially with lower range of ejection fraction (EF). Sodium-glucose co-transporter-2 inhibitors (SGLT2i)-empagliflozin and dapagliflozin and probably sotagliflozin are the only currently available drugs which have shown benefits in HFpEF, mostly by reducing hospitalizations. The benefit of SGLT2i is evident in both diabetic and nondiabetic subsets., (© Journal of the Association of Physicians of India 2011.)
- Published
- 2022
- Full Text
- View/download PDF
39. Managing patients of shock and acute kidney injury in tertiary care cardiac ICU: Experience with continuous renal replacement therapy.
- Author
-
Gupta V, Kapoor S, Makkar V, Chhabra ST, Aslam N, Mohan B, Kumar R, Pandey V, Prashar H, Kaur G, Grover S, Sethi S, Kaur S, Ralhan S, and Wander GS
- Subjects
- Humans, Intensive Care Units, Renal Replacement Therapy, Retrospective Studies, Tertiary Healthcare, Acute Kidney Injury epidemiology, Acute Kidney Injury therapy, Continuous Renal Replacement Therapy
- Abstract
Background: Clinical experience on details of CRRT initiation and outcomes in cardiac intensive care unit (CICU) patients is not available from developing countries like India. This study shares the 5-year clinical experience of managing CICU patients requiring CRRT in a tertiary care cardiac center of North India., Materials and Methods: Medical records of all CICU patients with acute kidney injury (AKI) managed by CRRT from October 2011 to September 2016 at tertiary referral center in North India were retrospectively reviewed. Multiple logistic regression analysis was used to identify predictors of post-CRRT mortality., Results: A total of 630 patients received CRRT during the study period. Most commonly AKI developed in patients with acute coronary syndrome (30.2 %) with cardiogenic shock. 55.9 % of the CRRT patients were >60 years of age, and/or on multiple supports in ICU including, mechanical ventilation, high doses of inotropes & vasopressors and other cardiovascular support. Of those on CRRT, 130 (20.6 %) patients had died, 215 (34.1 %) were discharged and 285 (45.2 %) could not complete the desired course. Multivariate regression analysis showed independent association of mortality with high vasoactive-inotropic score, single CRRT cycle and low mean arterial pressure in CRRT patients., Conclusion: About 34.1 % of patients receiving CRRT were alive at discharge, emphasizing the feasibility and utility of CRRT as a promising modality in this population for improving outcomes., Competing Interests: Declaration of competing interest There was no potential conflict of interest., (Copyright © 2021 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
40. Renal denervation therapy for hypertension: truths and half-truths: Renal denervation therapy for hypertension.
- Author
-
Ram CV, Iyengar SS, Wander G, Nair T, Kumar AS, Ray S, and Sharma S
- Abstract
Systemic hypertension is a major contributing factor for excessive morbidity and mortality globally. Experimental studies and early clinical trials showed excellent therapeutic responses to renal denervation (RDN) in patients with hypertension. However meta-analyses and objective assessments have failed to show that RDN therapy has any significant effect on blood pressure. The aim of this review is to introduce the different methods that can be used in RDN, along with the benefits and disadvantages of these methods. Radiofrequency (RF) ablation (of renal nerves) is the most com-mon method of RDN, and we discuss the clinical evaluation of this method in the SYMPLICITY RDN trials. Finally, the development of second-generation RF devices and more comprehensive RDN procedures lead us to consider the current status and future path for RDN., Competing Interests: The authors have no conflicts of interest to declare.
- Published
- 2021
- Full Text
- View/download PDF
41. Impact of the 2017 ACC/AHA guidelines on the prevalence of hypertension among Indian adults: Results from a cross-sectional survey.
- Author
-
Gupta K, Ramakrishnan S, Zachariah G, Rao JS, Mohanan PP, Venugopal K, Sateesh S, Sethi R, Jain D, Bardolei N, Mani K, Kakar TS, Jain V, Gupta P, Gupta R, Bansal S, Nath RK, Tyagi S, Wander GS, Gupta S, Mandal S, Senguttuvan NB, Subramanyam G, Roy D, Datta S, Ganguly K, Routray SN, Mishra SS, Singh BP, Bharti BB, Das MK, Deb PK, Deedwania P, and Seth A
- Abstract
Background: The impact of the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for diagnosis and management of hypertension on the prevalence of hypertension in India is unknown., Methods: We analyzed data from the Cardiac Prevent 2015 survey to estimate the change in the prevalence of hypertension. The JNC8 guidelines defined hypertension as a systolic blood pressure of ≥140 mmHg or diastolic blood pressure of ≥90 mmHg. The 2017 ACC/AHA guidelines define hypertension as a systolic blood pressure of ≥130 mmHg or diastolic blood pressure of ≥80 mmHg. We standardized the prevalence as per the 2011 census population of India. We also calculated the prevalence as per the World Health Organization (WHO) World Standard Population (2000-2025)., Results: Among 180,335 participants (33.2% women), the mean age was 40.6 ± 14.9 years (41.1 ± 15.0 and 39.7 ± 14.7 years in men and women, respectively). Among them, 8,898 (4.9%), 99,791 (55.3%), 35,694 (11.9%), 23,084 (12.8%), 9,989 (5.5%) and 2,878 (1.6%) participants belonged to age group 18-19, 20-44, 45-54, 55-64, 65-74 and ≥ 75 years respectively. The prevalence of hypertension according to the JNC8 and 2017 ACC/AHA guidelines was 29.7% and 63.8%, respectively- an increase of 115%. With the 2011 census population of India, this suggests that currently, 486 million Indian adults have hypertension according to the 2017 ACC/AHA guidelines, an addition of 260 million as compared to the JNC8 guidelines., Conclusion: According to the 2017 ACC/AHA guidelines, 3 in every 5 Indian adults have hypertension., Competing Interests: None of the authors have any conflict of interest to declare with this manuscript., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
42. Cardiological society of India document on safety measure during echo evaluation of cardiovascular disease in the time of COVID-19.
- Author
-
Gupta R, Das MK, Mohanan PP, Deb PK, Parashar SK, Chopra HK, Shrivastava S, Guha S, Goswami KC, Yadav R, Alagesan R, Amuthan V, Bansal M, Chakraborty RN, Chakraborti N, Chandra S, Chatterjee A, Chatterjee D, Chatterjee SS, Dutta AL, De A, Garg A, Garg VK, Goyal A, Goyal NK, Govind SC, Gupta VK, Hasija PK, Jabir A, Jain P, Jain V, Jayagopal PB, Kasliwal RR, Katyal VK, Kerkar PG, Khan AK, Khanna NN, Mandal M, Majumder B, Mishra SS, Meena CB, Naik N, Narain VS, Pancholia AK, Pathak LA, Ponde CK, Raghu K, Ray S, Roy D, Sarma D, Shanmugasundarum S, Singh BP, Tyagi S, Vijayaraghavan G, Wander GS, Wardhan H, and Nanda NC
- Subjects
- COVID-19, Cardiology, Cardiovascular Diseases epidemiology, Coronavirus Infections epidemiology, Female, Humans, India, Infection Control methods, Male, Pandemics statistics & numerical data, Pneumonia, Viral epidemiology, Practice Guidelines as Topic, Severe Acute Respiratory Syndrome epidemiology, Severe Acute Respiratory Syndrome prevention & control, Societies, Medical, Cardiovascular Diseases diagnostic imaging, Coronavirus Infections prevention & control, Cross Infection prevention & control, Echocardiography methods, Pandemics prevention & control, Patient Safety, Pneumonia, Viral prevention & control
- Abstract
An echocardiographic investigation is one of the key modalities of diagnosis in cardiology. There has been a rising presence of cardiological comorbidities in patients positive for COVID-19. Hence, it is becoming extremely essential to look into the correct safety precautions, healthcare professionals must take while conducting an echo investigation. The decision matrix formulated for conducting an echocardiographic evaluation is based on presence or absence of cardiological comorbidity vis-à-vis positive, suspected or negative for COVID-19. The safety measures have been constructed keeping in mind the current safety precautions by WHO, CDC and MoHFW, India., Competing Interests: Declaration of competing interest The author has none to declare., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF
43. Intra-operative uterine artery embolization with caesarean delivery in an adjoining operating theatre and catheter lab (OT/CL) complex vs. conventional management in patients with abnormally invasive placenta: a retrospective case control study.
- Author
-
Mohan B, Wander G, Bansal R, Mutti J, Tandon P, Juneja S, and Puri S
- Subjects
- Adult, Blood Transfusion statistics & numerical data, Case-Control Studies, Cesarean Section methods, Female, Humans, Hysterectomy statistics & numerical data, Length of Stay statistics & numerical data, Postpartum Hemorrhage etiology, Pregnancy, Retrospective Studies, Treatment Outcome, Cesarean Section adverse effects, Fertility Preservation methods, Placenta Diseases surgery, Postpartum Hemorrhage prevention & control, Uterine Artery Embolization methods
- Abstract
Patients of abnormally invasive placenta (AIP) undergoing caesarean delivery are at increased risk of haemorrhage. Conventional management includes piecemeal removal of placenta or placenta left in situ . However, they often require hysterectomy after delivery. Post-delivery prophylactic uterine artery embolisation (UAE) can help reduce morbidity and preserve fertility. We created an adjoining operating theatre and catheter lab (OT/CL complex). This is a retrospective case control study in which 37 patients of AIP were evaluated. Sixteen subjects (cases) had UAE immediately after caesarean delivery, and 21 subjects (controls) had usual care with traditional methods of controlling postpartum haemorrhage and hysterectomy where required. The hysterectomy rate (18.7% vs. 85.7%), mean duration of hospital stay (6.8 ± 2.6 vs. 13.9 ± 8.1) and number of units of blood transfusion required were significantly less in the case group as compared with controls. UAE is an effective conservative treatment along with caesarean delivery in patients with AIP.Impact statement What is already known? AIP is associated with high rates of PPH, maternal morbidity and mortality and need for hysterectomy after delivery. UAE has been advocated to preserve fertility and reduce PPH in these patients along with caesarean delivery. What do es the study add? We created an adjoining operating theatre and catheter lab (OT/CL complex) in a tertiary care centre and managed these patients with prompt UAE after caesarean delivery with team approach. We have shown significant reduction in morbidity and hospital stay with this coordinated management. What are the implications for clinical practice and/or further research? UAE with caesarean delivery is a preferred mode of delivery for patients of AIP. These patients should be diagnosed and referred to tertiary care centres with such facilities electively so as to provide optimal care to these patients. Cooperation between interventionist and obstetrician and adjoining availability of OT and catheter lab can further help in reducing the time to embolisation after delivery. A hybrid operating theatre with digital subtraction angiography (DSA) facilities would be ideal for the management of such patients.
- Published
- 2020
- Full Text
- View/download PDF
44. Cardiological society of India position statement on COVID-19 and heart failure.
- Author
-
Harikrishnan S, Mohanan PP, Chopra VK, Ambuj R, Sanjay G, Bansal M, Chakraborty RN, Chandra S, Chattarjee SS, Chopra HK, Mathew C, Deb PK, Goyal A, Goswami KC, Gupta R, Guha S, Gupta V, Hasija PK, Wardhan H, Jabir A, Jayagopal PB, Kahali D, Katyal VK, Kerkar PG, Khanna NN, Majumder B, Mandal M, Meena CB, Naik N, Narain VK, Pathak LA, Ray S, Roy D, Routray SN, Sarma D, Shanmugasundaram S, Singh BP, Tyagi SK, Venugopal K, Wander GS, Yadav R, and Das MK
- Subjects
- COVID-19, Comorbidity trends, Humans, India epidemiology, Pandemics, SARS-CoV-2, Betacoronavirus, Cardiology, Coronavirus Infections epidemiology, Heart Failure epidemiology, Pneumonia, Viral epidemiology, Societies, Medical
- Published
- 2020
- Full Text
- View/download PDF
45. Cardiological Society of India: Document on acute MI care during COVID-19.
- Author
-
Kerkar PG, Naik N, Alexander T, Bahl VK, Chakraborty RN, Chatterjee SS, Chopra HK, Dani SI, Deb PK, Goswami KC, Guha S, Gupta R, Gupta V, Hasija PK, Jayagopal PB, Justin Paul G, Kahali D, Katyal VK, Khanna NN, Mandal M, Mishra SS, Mohanan PP, Mullasari A, Mehta S, Pancholia AK, Ray S, Roy D, Shanmugasundarm S, Sharma S, Singh BP, Tewari S, Tyagi SK, Venugopal KN, Wander GS, Yadav R, and Das MK
- Subjects
- COVID-19, Cardiology, Coronavirus Infections epidemiology, Disease Management, Female, Humans, India, Male, Myocardial Infarction diagnosis, Pandemics statistics & numerical data, Patient Selection, Pneumonia, Viral epidemiology, Societies, Medical organization & administration, Treatment Outcome, Communicable Disease Control organization & administration, Coronavirus Infections prevention & control, Myocardial Infarction therapy, Outcome Assessment, Health Care, Pandemics prevention & control, Pneumonia, Viral prevention & control, Practice Guidelines as Topic standards
- Abstract
The unprecedented and rapidly spreading Coronavirus Disease-19 (COVID-19) pandemic has challenged public health care systems globally. Based on worldwide experience, India has initiated a nationwide lockdown to prevent the exponential surge of cases. During COVID-19, management of cardiovascular emergencies like acute Myocardial Infarction (MI) may be compromised. Cardiological Society of India (CSI) has ventured in this moment of crisis to evolve a consensus document for care of acute MI. However, this care should be individualized, based on local expertise and governmental advisories., Competing Interests: Conflict of interest There is no conflict of interest with either the corresponding author or any of the authors/co-authors., (Copyright © 2020 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
46. Kinase Inhibitors and Ovarian Cancer.
- Author
-
Katopodis P, Chudasama D, Wander G, Sales L, Kumar J, Pandhal M, Anikin V, Chatterjee J, Hall M, and Karteris E
- Abstract
Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of novel and more effective therapeutic strategies. In this mini review, we provide a summary of the current landscape of the clinical use of tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin (mTOR) inhibitors in ovarian cancer. Emerging data from phase I and II trials reveals that a combinatorial treatment that includes TKIs and chemotherapy agents seems promising in terms of PFS despite some adverse effects recorded; whereas the use of mTOR inhibitors seems less effective. There is a need for further research into the inhibition of multiple signaling pathways in ovarian cancer and progression to phase III trials for drugs that seem most promising.
- Published
- 2019
- Full Text
- View/download PDF
47. Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey.
- Author
-
Ramakrishnan S, Zachariah G, Gupta K, Shivkumar Rao J, Mohanan PP, Venugopal K, Sateesh S, Sethi R, Jain D, Bardolei N, Mani K, Kakar TS, Kidambi B, Bhushan S, Verma SK, Bhargava B, Roy A, Kothari SS, Gupta R, Bansal S, Sood S, Nath RK, Tyagi S, Gupta MD, Girish MP, Kalra IPS, Wander GS, Gupta S, Mandal S, Senguttuvan NB, Subramanyam G, Roy D, Datta S, Ganguly K, Routray SN, Mishra SS, Singh BP, Bharti BB, Das MK, Kumar S, Goswami KC, Bahl VK, Chandra S, Banerjee A, Guha S, Deb PK, Chopra HK, Deedwania P, and Seth A
- Subjects
- Adult, Aged, Blood Pressure Determination, Female, Humans, India epidemiology, Male, Middle Aged, Prevalence, Hypertension epidemiology
- Abstract
Objective: Hypertension is the most important risk factor for cardiovascular morbidity and mortality. There is limited data on hypertension prevalence in India. This study was conducted to estimate the prevalence of hypertension among Indian adults., Methods: A national level survey was conducted with fixed one-day blood pressure measurement camps across 24 states and union territories of India. Hypertension was defined as systolic blood pressure (BP) ≥140 mmHg or a diastolic BP ≥90 mmHg or on treatment for hypertension. The prevalence was age- and gender-standardized according to the 2011 census population of India., Results: Blood pressure was recorded for 180,335 participants (33.2% women; mean age 40.6 ± 14.9 years). Among them, 8,898 (4.9%), 99,791 (55.3%), 35,694 (11.9%), 23,084 (12.8%), 9,989 (5.5%), and 2,878 (1.6%) participants were of the age group 18-19, 20-44, 45-54, 55-64, 65-74, and ≥ 75 years, respectively. Overall prevalence of hypertension was 30.7% (95% confidence interval [CI]: 30.5, 30.9) and the prevalence among women was 23.7% (95% CI: 23.3, 24). Prevalence adjusted for 2011 census population and the WHO reference population was 29.7% and 32.8%, respectively., Conclusion: There is a high prevalence of hypertension, with almost one in every three Indian adult affected., (Copyright © 2019 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
48. Appropriate use of PCSK9 Inhibitors in India.
- Author
-
Iyengar SS, Bansal M, Sawhney J, Wander G, Narasingan SN, Chandra KS, D P, Nair T, Krishnakumar B, Deshpande N, Bardoloi N, Shetty S, Desai N, Pancholia AK, and Swamy A
- Subjects
- Anticholesteremic Agents, Cholesterol, LDL, India, Proprotein Convertase 9 metabolism, Enzyme Inhibitors therapeutic use, PCSK9 Inhibitors
- Abstract
The burden of atherosclerotic cardiovascular (CV) disease is alarmingly high and increasing in our country. Dyslipidemia is one of the major modifiable risk factors, and INTERHEART study showed that dyslipidemia had the highest population attributable risk for myocardial infarction. In the management of dyslipidemia, low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target. In addition to therapeutic lifestyle changes, statins and ezetimibe effectively lower LDL-C and consequently improve CV outcomes. However, there are situations where these drugs fall short of achieving the target or they may not be well tolerated., (© Journal of the Association of Physicians of India 2011.)
- Published
- 2019
49. Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry.
- Author
-
Rogers-Broadway KR, Kumar J, Sisu C, Wander G, Mazey E, Jeyaneethi J, Pados G, Tsolakidis D, Klonos E, Grunt T, Hall M, Chatterjee J, and Karteris E
- Subjects
- Cell Line, Tumor, Female, Humans, Signal Transduction, Endometriosis genetics, Mechanistic Target of Rapamycin Complex 1 metabolism, Mechanistic Target of Rapamycin Complex 2 metabolism, Ovarian Neoplasms genetics, Protein Kinase Inhibitors pharmacology, TOR Serine-Threonine Kinases metabolism
- Abstract
Endometriosis is a well‑known risk factor for ovarian cancer. The genetic changes that characterise endometriosis are poorly understood; however, the mechanistic target of rapamycin (mTOR) pathway is involved. In this study, we investigated the expression of key mTOR components in endometriosis and the effects of rapalogues using an endometrioid ovarian carcinoma cell line (MDAH 2774) as an in vitro model. Gene expression of mTOR, DEPTOR, Rictor and Raptor was assessed by qPCR in 24 endometriosis patients and in silico in ovarian cancer patients. Furthermore, the effects of Rapamycin, Everolimus, Deforolimus, Temsirolimus, Resveratrol, and BEZ235 (Dactolisib, a dual kinase inhibitor) on mTOR signalling components was assessed. mTOR showed a significant increase in the expression in endometriosis and ovarian endometrioid adenocarcinoma patients compared to non‑affected controls. DEPTOR, an inhibitor of mTOR, was downregulated in the advanced stages of ovarian cancer (III and IV) compared to earlier stages (I and II). Treatment of MDAH‑2774 cells with the mTOR inhibitors resulted in the significant upregulation of DEPTOR mRNA, whereas treatment with rapamycin and BEZ‑235 (100 nM) resulted in downregulation of the mTOR protein expression after 48 h of treatment. None of the treatments resulted in translocation of mTOR from cytoplasm to nucleus. Upregulation of DEPTOR is a positive prognostic marker in ovarian cancer and is increased in response to mTOR pathway inhibition suggesting that it functions as a tumour suppressor gene in endometrioid ovarian carcinoma. Collectively, our data suggest the mTOR pathway as a potential connection between endometriosis and ovarian cancer and may be a potential target in the treatment of both conditions.
- Published
- 2019
- Full Text
- View/download PDF
50. Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India.
- Author
-
Guha S, Sethi R, Ray S, Bahl VK, Shanmugasundaram S, Kerkar P, Ramakrishnan S, Yadav R, Chaudhary G, Kapoor A, Mahajan A, Sinha AK, Mullasari A, Pradhan A, Banerjee AK, Singh BP, Balachander J, Pinto B, Manjunath CN, Makhale C, Roy D, Kahali D, Zachariah G, Wander GS, Kalita HC, Chopra HK, Jabir A, Tharakan J, Paul J, Venogopal K, Baksi KB, Ganguly K, Goswami KC, Somasundaram M, Chhetri MK, Hiremath MS, Ravi MS, Das MK, Khanna NN, Jayagopal PB, Asokan PK, Deb PK, Mohanan PP, Chandra P, Girish CR, Rabindra Nath O, Gupta R, Raghu C, Dani S, Bansal S, Tyagi S, Routray S, Tewari S, Chandra S, Mishra SS, Datta S, Chaterjee SS, Kumar S, Mookerjee S, Victor SM, Mishra S, Alexander T, Samal UC, and Trehan V
- Subjects
- Humans, India, Cardiology, Disease Management, Myocardial Reperfusion methods, ST Elevation Myocardial Infarction therapy, Societies, Medical
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.